AACE MENA 2025-Adrenocortical Cancer: New Advances

Video Transcription

Video Summary

The talk addresses prognostic factors and evolving treatments for adrenocortical carcinoma (ACC), a rare and aggressive cancer. Key prognostic indicators include disease stage, surgical margins, KI-67 proliferation index, hormonal activity, and genetic/molecular profiles. These factors help predict recurrence risk and guide adjuvant therapy decisions. Complete tumor resection offers the only curative option, but recurrence rates are high. Mitotane, the only approved antineoplastic drug for ACC, improves survival but has side effects; current trials are evaluating its use alone or combined with chemotherapy in high-risk patients. Adjuvant radiotherapy may reduce local recurrence but shows mixed survival benefits. Immunotherapy and targeted therapies, including pembrolizumab and multikinase inhibitors like cabozantinib and lenvatinib, are promising salvage treatments. Ongoing research explores combining these modalities. Ultimately, integrating clinical, pathological, and molecular data enhances risk stratification, enabling tailored adjuvant treatments to improve outcomes in ACC patients.

Keywords

adrenocortical carcinoma

prognostic factors

mitotane therapy

immunotherapy

targeted therapies